

Dorien H Nieman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7107413/dorien-h-nieman-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

104
papers

3,467
citations

33
h-index

56
g-index

112
ext. papers

4,213
ext. citations

5.2
avg, IF

4.83
L-index

#	Paper	IF	Citations
104	The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial. <i>Brain, Behavior, and Immunity</i> , 2022 , 99, 147-156	16.6	0
103	Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosis. <i>Microbial Biotechnology</i> , 2021 , 15, 874-881	3.3	3
102	Online Indicated Preventive Mental Health Interventions for Youth: A Scoping Review. <i>Frontiers in Psychiatry</i> , 2021 , 12, 580843	5	4
101	The relationship between cognitive functioning and psychopathology in patients with psychiatric disorders: a transdiagnostic network analysis. <i>Psychological Medicine</i> , 2021 , 1-10	6.9	0
100	The Collaborative Outcomes study on Health and Functioning during Infection Times in Adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic.. <i>Journal of Affective Disorders</i> , 2021 , 299, 393-393	6.6	2
99	Prediction of clinical outcomes beyond psychosis in the ultra-high risk for psychosis population. <i>Microbial Biotechnology</i> , 2021 , 15, 642-651	3.3	4
98	Resting-state brain oscillations predict cognitive function in psychiatric disorders: A transdiagnostic machine learning approach. <i>NeuroImage: Clinical</i> , 2021 , 30, 102617	5.3	1
97	Greater preference for eveningness is associated with negative symptoms in an ultra-high risk for psychosis sample. <i>Microbial Biotechnology</i> , 2021 , 15, 1793-1798	3.3	1
96	Efficacy of a transdiagnostic ecological momentary intervention for improving self-esteem (SELFIE) in youth exposed to childhood adversity: study protocol for a multi-center randomized controlled trial. <i>Trials</i> , 2021 , 22, 641	2.8	1
95	Characterization and prediction of clinical pathways of vulnerability to psychosis through graph signal processing. <i>ELife</i> , 2021 , 10,	8.9	1
94	Primary prevention of depression: An umbrella review of controlled interventions. <i>Journal of Affective Disorders</i> , 2021 , 294, 957-970	6.6	8
93	The association between migrant status and transition in an ultra-high risk for psychosis population. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021 , 56, 943-952	4.5	0
92	Protocol Across study: longitudinal transdiagnostic cognitive functioning, psychiatric symptoms, and biological parameters in patients with a psychiatric disorder. <i>BMC Psychiatry</i> , 2020 , 20, 212	4.2	4
91	Do schizotypal or borderline personality disorders predict onset of psychotic disorder or persistent attenuated psychotic symptoms in patients at high clinical risk?. <i>Schizophrenia Research</i> , 2020 , 220, 275-277	3.6	2
90	Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention. <i>JAMA Psychiatry</i> , 2020 , 77, 755-765	14.5	143
89	Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial. <i>Schizophrenia Research</i> , 2020 , 218, 48-54	3.6	4
88	Basic symptoms in young people at ultra-high risk of psychosis: Association with clinical characteristics and outcomes. <i>Schizophrenia Research</i> , 2020 , 216, 255-261	3.6	8

87	Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial. <i>Behaviour Research and Therapy</i> , 2020 , 124, 103527	5.2	7
86	What is good mental health? A scoping review. <i>European Neuropsychopharmacology</i> , 2020 , 31, 33-46	1.2	40
85	T34. THE IMPACT OF ANTIDEPRESSANT USE ON THE TRANSITION TO PSYCHOSIS RATE IN THE NEURAPRO TRIAL. <i>Schizophrenia Bulletin</i> , 2020 , 46, S244-S245	1.3	78
84	Universal and selective interventions to promote good mental health in young people: Systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2020 , 41, 28-39	1.2	25
83	The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis. <i>Biological Psychiatry</i> , 2020 , 87, 243-252	7.9	22
82	Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis. <i>Schizophrenia Research</i> , 2020 , 226, 52-60	3.6	0
81	Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people. <i>Schizophrenia Research</i> , 2020 , 226, 44-51	3.6	14
80	Belgian Superior Health Council advises against the use of the DSM categories. <i>Lancet Psychiatry</i> , 2019 , 6, 726	23.3	7
79	Individualized Prediction of Transition to Psychosis in 1,676 Individuals at Clinical High Risk: Development and Validation of a Multivariable Prediction Model Based on Individual Patient Data Meta-Analysis. <i>Frontiers in Psychiatry</i> , 2019 , 10, 345	5	18
78	The relationship between childhood trauma and clinical characteristics in ultra-high risk for psychosis youth. <i>Psychosis</i> , 2019 , 11, 28-41	1.2	4
77	The validation of a new online cognitive assessment tool: The MyCognition Quotient. <i>International Journal of Methods in Psychiatric Research</i> , 2019 , 28, e1775	4.3	16
76	Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial. <i>Frontiers in Psychiatry</i> , 2019 , 10, 393	5	13
75	European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP). <i>European Neuropsychopharmacology</i> , 2019 , 29, 1301-1311	1.2	22
74	Points to consider regarding DSM alternatives - AuthorsReply. <i>Lancet Psychiatry</i> , 2019 , 6, 895	23.3	
73	Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial. <i>Schizophrenia Research</i> , 2019 , 206, 67-74	3.6	25
72	Expressed emotion as a predictor of the first psychotic episode - Results of the European prediction of psychosis study. <i>Schizophrenia Research</i> , 2018 , 199, 346-352	3.6	9
71	Clinical trajectories in the ultra-high risk for psychosis population. <i>Schizophrenia Research</i> , 2018 , 197, 550-556	3.6	34
70	The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quo. <i>Schizophrenia Research</i> , 2018 , 195, 543-548	3.6	20

69	Dynamic prediction of transition to psychosis using joint modelling. <i>Schizophrenia Research</i> , 2018 , 202, 333-340	3.6	13
68	The interaction between cannabis use and the Val158Met polymorphism of the COMT gene in psychosis: A transdiagnostic meta - analysis. <i>PLoS ONE</i> , 2018 , 13, e0192658	3.7	13
67	T49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION. <i>Schizophrenia Bulletin</i> , 2018 , 44, S132-S133	1.3	3
66	T9. CROSS-SECTIONAL ASSOCIATION OF MEMBRANE FATTY ACID COMPOSITION AND PSYCHOPATHOLOGY IN THE NEURAPRO-E STUDY. <i>Schizophrenia Bulletin</i> , 2018 , 44, S116-S116	1.3	1
65	F25. NEURAPRO REVISITED: INCREASES IN LONG-CHAIN OMEGA-3 FATTY ACIDS IMPROVE FUNCTIONAL AND SYMPTOMATIC OUTCOMES IN ULTRAHIGH RISK PATIENTS. <i>Schizophrenia Bulletin</i> , 2018 , 44, S228-S228	1.3	1
64	S136. A NOVEL APPROACH FOR DEVELOPING PREDICTION MODEL OF TRANSITION TO PSYCHOSIS: DYNAMIC PREDICTION USING JOINT MODELLING. <i>Schizophrenia Bulletin</i> , 2018 , 44, S378-S379	1.3	1
63	O8.8. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL. <i>Schizophrenia Bulletin</i> , 2018 , 44, S99-S99	1.3	1
62	The Prodromal Questionnaire: a case for IRT-based adaptive testing of psychotic experiences?. <i>International Journal of Methods in Psychiatric Research</i> , 2017 , 26,	4.3	8
61	Effect of Ω Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial. <i>JAMA Psychiatry</i> , 2017 , 74, 19-27	14.5	162
60	Cerebral dopamine deficiency, plasma monoamine alterations and neurocognitive deficits in adults with phenylketonuria. <i>Psychological Medicine</i> , 2017 , 47, 2854-2865	6.9	18
59	Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis. <i>Psychotherapy and Psychosomatics</i> , 2017 , 86, 292-299	9.4	17
58	174.2 Psychosis Prediction: Stratification of Risk Estimation With Information-Processing and Premorbid Functioning Variables. <i>Schizophrenia Bulletin</i> , 2017 , 43, S87-S88	1.3	78
57	Four-Year Cost-effectiveness of Cognitive Behavior Therapy for Preventing First-episode Psychosis: The Dutch Early Detection Intervention Evaluation (EDIE-NL) Trial. <i>Schizophrenia Bulletin</i> , 2017 , 43, 365-374	1.3	22
56	The effect of childhood adversity on 4-year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE-NL) Trial. <i>Psychiatry Research</i> , 2017 , 247, 55-62	9.9	16
55	Distinct white-matter aberrations in 22q11.2 deletion syndrome and patients at ultra-high risk for psychosis. <i>Psychological Medicine</i> , 2016 , 46, 2299-311	6.9	17
54	Four-Year Follow-up of Cognitive Behavioral Therapy in Persons at Ultra-High Risk for Developing Psychosis: The Dutch Early Detection Intervention Evaluation (EDIE-NL) Trial. <i>Schizophrenia Bulletin</i> , 2016 , 42, 1243-52	1.3	48
53	Heterogeneity of Psychosis Risk Within Individuals at Clinical High Risk: A Meta-analytical Stratification. <i>JAMA Psychiatry</i> , 2016 , 73, 113-20	14.5	270
52	Cortical Morphology Differences in Subjects at Increased Vulnerability for Developing a Psychotic Disorder: A Comparison between Subjects with Ultra-High Risk and 22q11.2 Deletion Syndrome. <i>PLoS ONE</i> , 2016 , 11, e0159928	3.7	16

51	Development of a stage-dependent prognostic model to predict psychosis in ultra-high-risk patients seeking treatment for co-morbid psychiatric disorders. <i>Psychological Medicine</i> , 2016 , 46, 1839-51	6.9	12
50	COMT Val(158)Met genotype and cannabis use in people with an At Risk Mental State for psychosis: Exploring Gene x Environment interactions. <i>Schizophrenia Research</i> , 2016 , 174, 24-28	3.6	17
49	Adapted cognitive-behavioural therapy required for targeting negative symptoms in schizophrenia: meta-analysis and meta-regression. <i>Psychological Medicine</i> , 2015 , 45, 453-65	6.9	96
48	Cost-effectiveness of preventing first-episode psychosis in ultra-high-risk subjects: multi-centre randomized controlled trial. <i>Psychological Medicine</i> , 2015 , 45, 1435-46	6.9	41
47	Qualitative and quantitative aspects of information processing in first psychosis: latent class analyses in patients, at-risk subjects, and controls. <i>Psychophysiology</i> , 2015 , 52, 585-93	4.1	2
46	Sensory gating in subjects at ultra high risk for developing a psychosis before and after a first psychotic episode. <i>World Journal of Biological Psychiatry</i> , 2015 , 16, 12-21	3.8	27
45	Detection and treatment of at-risk mental state for developing a first psychosis: making up the balance. <i>Lancet Psychiatry</i> , 2015 , 2, 825-34	23.3	32
44	Childhood trauma and clinical outcome in patients at ultra-high risk of transition to psychosis. <i>Schizophrenia Research</i> , 2015 , 169, 193-198	3.6	28
43	Cognitive effects of deep brain stimulation in patients with obsessive-compulsive disorder. <i>Journal of Psychiatry and Neuroscience</i> , 2015 , 40, 378-86	4.5	18
42	New treatments for psychotic disorders. <i>Lancet Psychiatry</i> , 2015 , 2, 282-3	23.3	
41	Psychosis prediction: stratification of risk estimation with information-processing and premorbid functioning variables. <i>Schizophrenia Bulletin</i> , 2014 , 40, 1482-90	1.3	75
40	The distribution of self-reported psychotic-like experiences in non-psychotic help-seeking mental health patients in the general population; a factor mixture analysis. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2014 , 49, 349-58	4.5	15
39	PREVENTIVE PSYCHOTHERAPY. <i>Schizophrenia Research</i> , 2014 , 153, S42-S43	3.6	1
38	Can quantitative EEG measures predict clinical outcome in subjects at Clinical High Risk for psychosis? A prospective multicenter study. <i>Schizophrenia Research</i> , 2014 , 153, 42-7	3.6	38
37	Effects of cannabis use on event related potentials in subjects at ultra high risk for psychosis and healthy controls. <i>International Journal of Psychophysiology</i> , 2013 , 88, 149-56	2.9	10
36	Quantitative and qualitative symptomatic differences in individuals at Ultra-High Risk for psychosis and healthy controls. <i>Psychiatry Research</i> , 2013 , 210, 432-7	9.9	10
35	Psychosocial outcome in patients at clinical high risk of psychosis: a prospective follow-up. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2013 , 48, 303-11	4.5	27
34	Depression and social anxiety in help-seeking patients with an ultra-high risk for developing psychosis. <i>Psychiatry Research</i> , 2013 , 209, 309-13	9.9	44

33	The Strauss and Carpenter Prognostic Scale in subjects clinically at high risk of psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2013 , 127, 53-61	6.5	23
32	Is a schizo-obsessive subtype associated with cognitive impairment? Results from a large cross-sectional study in patients with psychosis and their unaffected relatives. <i>Journal of Nervous and Mental Disease</i> , 2013 , 201, 30-5	1.8	18
31	Detection of people at risk of developing a first psychosis: comparison of two recruitment strategies. <i>Acta Psychiatrica Scandinavica</i> , 2012 , 126, 21-30	6.5	60
30	The validity of the 16-item version of the Prodromal Questionnaire (PQ-16) to screen for ultra high risk of developing psychosis in the general help-seeking population. <i>Schizophrenia Bulletin</i> , 2012 , 38, 1288-96	1.3	191
29	Cannabis use and age at onset of symptoms in subjects at clinical high risk for psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2012 , 125, 45-53	6.5	61
28	Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. <i>Schizophrenia Bulletin</i> , 2012 , 38, 1180-8	1.3	135
27	Ethnicity and baseline symptomatology in patients with an At Risk Mental State for psychosis. <i>Psychological Medicine</i> , 2012 , 42, 247-56	6.9	14
26	Environmental factors and social adjustment as predictors of a first psychosis in subjects at ultra high risk. <i>Schizophrenia Research</i> , 2011 , 125, 69-76	3.6	70
25	Ultra high-risk state for psychosis and non-transition: a systematic review. <i>Schizophrenia Research</i> , 2011 , 132, 8-17	3.6	109
24	Auditory ERP components before and after transition to a first psychotic episode. <i>Biological Psychology</i> , 2011 , 87, 350-7	3.2	34
23	Social disability at admission for a first psychosis does not predict clinical outcome at 5-year follow-up. <i>Journal of Nervous and Mental Disease</i> , 2011 , 199, 510-2	1.8	5
22	Three-year course of clinical symptomatology in young people at ultra high risk for transition to psychosis. <i>Acta Psychiatrica Scandinavica</i> , 2011 , 123, 36-42	6.5	36
21	Semantic fluency deficits and reduced grey matter before transition to psychosis: a voxelwise correlational analysis. <i>Psychiatry Research - Neuroimaging</i> , 2011 , 194, 1-6	2.9	22
20	Factor analysis of the scale of prodromal symptoms: differentiating between negative and depression symptoms. <i>Psychopathology</i> , 2011 , 44, 379-85	3.4	18
19	Neurocognitive functioning before and after the first psychotic episode: does psychosis result in cognitive deterioration?. <i>Psychological Medicine</i> , 2010 , 40, 1599-606	6.9	77
18	Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls. <i>Australian and New Zealand Journal of Psychiatry</i> , 2010 , 44, 230-6	2.6	37
17	White-matter markers for psychosis in a prospective ultra-high-risk cohort. <i>Psychological Medicine</i> , 2010 , 40, 1297-304	6.9	111
16	Reduced parietal P300 amplitude is associated with an increased risk for a first psychotic episode. <i>Biological Psychiatry</i> , 2010 , 68, 642-8	7.9	74

15	Increased saccadic rate during smooth pursuit eye movements in patients at Ultra High Risk for developing a psychosis. <i>Brain and Cognition</i> , 2010 , 73, 215-21	2.7	18
14	Verbal fluency as a possible predictor for psychosis. <i>European Psychiatry</i> , 2010 , 25, 105-10	6	46
13	Age of onset of cannabis use is associated with age of onset of high-risk symptoms for psychosis. <i>Canadian Journal of Psychiatry</i> , 2010 , 55, 165-71	4.8	43
12	Disability in people clinically at high risk of psychosis. <i>British Journal of Psychiatry</i> , 2010 , 197, 278-84	5.4	101
11	Diagnostic validity of the Eppendorf Schizophrenia Inventory (ESI): a self-report screen for ultrahigh risk and acute psychosis. <i>Psychological Assessment</i> , 2010 , 22, 935-44	5.3	9
10	A single blind randomized controlled trial of cognitive behavioural therapy in a help-seeking population with an At Risk Mental State for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-NL) trial. <i>Trials</i> , 2010 , 11, 30	2.8	43
9	Reduced context effects on retrieval in first-episode schizophrenia. <i>PLoS ONE</i> , 2010 , 5, e10356	3.7	23
8	Early intervention in patients at ultra high risk of psychosis: benefits and risks. <i>Acta Psychiatrica Scandinavica</i> , 2009 , 119, 426-42	6.5	60
7	Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis. <i>Schizophrenia Research</i> , 2009 , 109, 60-5	3.6	151
6	Prescription of antipsychotic medication to patients at ultra high risk of developing psychosis. <i>International Clinical Psychopharmacology</i> , 2009 , 24, 223-8	2.2	20
5	Antisaccade task performance in patients at ultra high risk for developing psychosis. <i>Schizophrenia Research</i> , 2007 , 95, 54-60	3.6	51
4	Cognitieve gedragstherapie bij jongeren met risicosymptomen voor een psychose. <i>Kind & Adolescent Praktijk</i> , 2007 , 6, 3-7	0	
3	Clinical and neuropsychological correlates of the P300 in schizophrenia. <i>Schizophrenia Research</i> , 2002 , 55, 105-13	3.6	41
2	Neurofysiologische en neuropsychologische correlaten van schizofrenie. <i>Neuropraxis</i> , 1999 , 3, 93-97	0	
1	CBT for Those at Risk of a First Episode Psychosis		22